Navigation Links
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
Date:4/23/2009

n, treatment or cure of any disease or illness. It may not be sold or promoted in the United States unless and until approved for marketing by the FDA. Similar restrictions apply in other countries.

About Study 204

In the Phase IIb study (previously disclosed as Study 204), 278 treatment naive, genotype 1 patients were randomized with the following patient demographics: mean age 48.8 yrs, 61.1% male, 30% African-American or Latino, 80.7% viral load ¿400,000 IU/mL and 82.1 kg mean weight. Week (TW) 60 efficacy and safety results for the intention-to-treat (ITT) population are shown in the table above.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including, but not limited to, statements regarding the potential for taribavirin in the treatment of hepatitis C, and the continuing role of ribavirin or taribavirin in the treatment of hepatitis C, that are based on management's current expectations and involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to the clinical development of new products, regulatory approval processes, that results from week 60 in the phase IIb clinical trial are not necessarily predictive of the entire phase IIb trial or a phase III trial, and other risks as set forth under the caption Risk Factors in the company's most recent annual or quarterly report filed with the SEC, which factors are incorporated h
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
2. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
3. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
6. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
7. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
8. Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
9. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
10. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
11. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... July 13, 2014 Recently, 2014QuinceaneraDresses.com, ... has unveiled its new range of gorgeous ... market, the demand for elegant Quinceanera outfits is ... beautiful items. All the company’s newly released dresses ... They are all elegant and vivid. , ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the ... 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed ... (AGR) of 4.35%, during the forecast period. In 2023, ... incident cases of aGVHD in the 6MM, with 4,989 ... number of diagnosed incident cases of aGVHD, with 704 ...
(Date:7/13/2014)... 13, 2014 A decreased ability to identify ... and Alzheimer,s disease, while examinations of the eye ... associated with Alzheimer,s, in the brain, according to ... at the Alzheimer,s Association International Conference 2014 (AAIC ... studies, the decreased ability to identify odors was ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 Wright ... bellwether trial has been scheduled in July of 2015, ... Lipitor lawsuits are in the discovery process ... Richard M. Gergel is presiding over the multidistrict litigation ... filed on behalf of individuals who allege that they ...
Breaking Medicine News(10 mins):Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4
... - The Lancet Launches a New Initiative ... an Archive of Science for Health and Human,Development, ... the launch of a new, editorially,independent global health ... ., The network will search and archive ...
... 7, 2008 Varian, Inc.,(NasdaqGS: VARI) announced today ... owned company based in Abingdon, U.K. Oxford Diffraction,is ... used by,scientists in pharmaceutical research and other research ... and large molecules such as,proteins., For crystalline ...
... Schoolchildren who required surgery as infants for congenital ... having problems with inattention and hyperactivity, and often ... at risk for academic and behavior problems, and ... provide them with ongoing follow-up and neurodevelopmental screening, ...
... 2008 News stories about an allegedly harmful link ... onset of autism had little effect on whether U.S. ... immunization records and news stories. Parents decisions were more ... researchers said. , Researchers from The Children,s Hospital of ...
... Ingrid Bells turn at bat. She steps up to the plate, ... and connects with the ball. , Foul ball! Everyone cheers for ... a field, and theres no real bat or ball to be ... her occupational therapy. She is among 30 Parkinsons disease patients participating ...
... data of 221 men and women found that the ... death showed evidence of small, cumulative blood vessel damage ... Thomas Montine and colleagues analyzed the brain tissue of ... study, wherein 3,400 adult participants (65+) in the Seattle ...
Cached Medicine News:Health News:The Lancet Global Health Network 2Health News:The Lancet Global Health Network 3Health News:The Lancet Global Health Network 4Health News:Varian, Inc. Acquires Oxford Diffraction, Ltd. 2Health News:Varian, Inc. Acquires Oxford Diffraction, Ltd. 3Health News:For children with heart disease, a risk of attention and behavior problems 2Health News:Parents follow pediatrician advice on administering MMR vaccinations 2Health News:Parents follow pediatrician advice on administering MMR vaccinations 3Health News:Occupational therapists use Wii for Parkinson's study 2
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... July 10, 2014  The U.S. Department of Health ... to University Hospitals (UH) Case Medical Center Seidman Cancer ... model aimed at improving care for patients with complex ... project will test a unique model developed at UH ... disease, significant comorbidities, or demonstrated need for high health ...
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
7 1/2" Bayonet Monopolar Forceps, Ins., Serrated...
Extended blade - 25/box....
... and workmanship are the hallmark of these ... in mind. The top (incident) circular 9W ... shadows while remaining cool to the touch. ... with 10x to 44x zoom magnification or ...
... Nikon's evanescent wave imaging system utilizes ... molecules in the thin section in ... structure". This unique design permits simultaneous ... illumination systems, with no restriction on ...
Medicine Products: